Eli Lilly and Company $LLY Shares Sold by First American Bank

First American Bank decreased its position in Eli Lilly and Company (NYSE:LLY) by 1.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,156 shares of the company’s stock after selling 872 shares during the period. Eli Lilly and Company makes up approximately 2.5% of First American Bank’s holdings, making the stock its 10th biggest position. First American Bank’s holdings in Eli Lilly and Company were worth $39,795,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Wealth Quarterback LLC boosted its position in shares of Eli Lilly and Company by 22.8% during the third quarter. Wealth Quarterback LLC now owns 1,749 shares of the company’s stock worth $1,335,000 after buying an additional 325 shares during the period. waypoint wealth counsel raised its stake in Eli Lilly and Company by 14.3% during the 3rd quarter. waypoint wealth counsel now owns 719 shares of the company’s stock valued at $549,000 after acquiring an additional 90 shares in the last quarter. Oak Harvest Investment Services boosted its position in Eli Lilly and Company by 103.5% during the 3rd quarter. Oak Harvest Investment Services now owns 8,087 shares of the company’s stock worth $6,170,000 after acquiring an additional 4,114 shares during the period. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Eli Lilly and Company by 41.3% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 48,915 shares of the company’s stock worth $37,322,000 after purchasing an additional 14,301 shares in the last quarter. Finally, Plimoth Trust Co. LLC grew its stake in shares of Eli Lilly and Company by 3.9% in the third quarter. Plimoth Trust Co. LLC now owns 8,501 shares of the company’s stock worth $6,486,000 after purchasing an additional 321 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. HSBC restated a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a report on Thursday, December 18th. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Scotiabank initiated coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price for the company. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Stock Up 0.1%

LLY stock opened at $1,079.84 on Wednesday. The firm has a market cap of $1.02 trillion, a PE ratio of 52.83, a P/E/G ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a 50 day simple moving average of $997.74 and a 200 day simple moving average of $845.33.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 earnings per share. The firm’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.